Strong earnings Fisher & Paykel Healthcare reported its biggest annual profit in history with net earnings rising 24 percent to about 468.5 million NZD for the year ended 31 March 2026, signaling solid financial health and potential capacity for expanded hospital and clinical equipment orders.

Award momentum Recent awards for investor relations and ESG reporting enhance credibility and visibility with investors and healthcare buyers, creating warmer introductions for potential large contract discussions and lengthening enterprise sales cycles.

Sleep and respiratory focus Product launches and ongoing CPAP mask innovations (Evora Full Face Mask, F&P Nova Nasal mask) indicate a strong market push in sleep apnea and respiratory care, suggesting cross-sell opportunities for complementary devices, masks, and related accessories.

Strategic leadership Appointment of a non-executive director, Mark Cross, and a growing leadership profile support governance credibility and potential for expanding into new markets or channels through strengthened strategic partnerships.

Market expansion Continued product development and marketing emphasis, including consumer-facing apps and design-led solutions (Care by Design), point to opportunities for hospital systems, homecare programs, and international distributors to adopt integrated care ecosystems.